Prostate Cancer Screening

Screening tests for prostate cancer can include both the digital rectal exam (DRE) and prostate-specific antigen (PSA) test. Some tests like the DRE are not very sensitive and can miss many early prostate cancers.

Other tests, like the PSA test, can generate a significant number of false positive results due to low specificity. Some men with higher than normal PSA levels may have a common, noncancerous condition called benign prostatic hyperplasia (BPH) and simply need to be observed over time through active surveillance.

At Fox Chase Cancer Center we strive to minimize over-treatment of patients with low-risk prostate cancer while using the latest clinical tools to treat those individuals with more aggressive prostate tumors. To this end, many patients with low-risk disease are offered active surveillance by our prostate cancer specialists, while African American men and all men with a family history of prostate cancer are invited to participate in a special monitoring program at Fox Chase called the Risk Assessment Program.

Each patient’s age and risk must be considered when determining the right approach to screening for prostate cancer. The prostate cancer specialists at Fox Chase have extensive experience with managing the screening of prostate cancer. For more information, see the American Urological Association’s guidelines for the early detection of prostate cancer.